161 related articles for article (PubMed ID: 36350405)
1. [Nephrological management and drug dosing in patients with rheumatic diseases and renal insufficiency].
Weiner SM
Z Rheumatol; 2022 Dec; 81(10):811-828. PubMed ID: 36350405
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of rheumatic disease with renal insufficiency].
Weiner SM
Orthopade; 2019 Nov; 48(11):927-935. PubMed ID: 31531703
[TBL] [Abstract][Full Text] [Related]
3. [Dosage and toxicity of antirheumatic drugs in renal insufficiency].
Weiner SM; Bergner R
Z Rheumatol; 2015 May; 74(4):300-9. PubMed ID: 25962451
[TBL] [Abstract][Full Text] [Related]
4. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
[TBL] [Abstract][Full Text] [Related]
5. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
7. [Management of antirheumatic drugs in kidney failure].
Manganelli R; Manganelli S; Iannaccone S; De Simone W
G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845207
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
9. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
11. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of cardiovascular risk factors].
Krüger K
Z Rheumatol; 2016 Mar; 75(2):173-80; quiz 181-2. PubMed ID: 26924198
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
14. Systemic rheumatic diseases: From biological agents to small molecules.
Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
[TBL] [Abstract][Full Text] [Related]
15. Dosing of antirheumatic drugs in renal disease and dialysis.
Swarup A; Sachdeva N; Schumacher HR
J Clin Rheumatol; 2004 Aug; 10(4):190-204. PubMed ID: 17043508
[TBL] [Abstract][Full Text] [Related]
16. [Rheumatic diseases, inflammation and cardiovascular risk].
Nguyen P; Baerwald C
Dtsch Med Wochenschr; 2021 Apr; 146(7):474-477. PubMed ID: 33780995
[TBL] [Abstract][Full Text] [Related]
17. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
18. [Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].
Albrecht K; Poddubnyy D; Leipe J; Sewerin P; Iking-Konert C; Scholz R; Krüger K
Z Rheumatol; 2022 Apr; 81(3):212-224. PubMed ID: 34928422
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
